Chile - español - ISPC (Instituto de Salud Pública de Chile)

merck sharp & dohme (i.a.) llc - aprepitant - sin formulas

Unión Europea - español - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - la esclerosis múltiple remitente-recurrente - inmunosupresores - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Unión Europea - español - EMA (European Medicines Agency)

laboratorios lesvi s.l. - fumarato de dimetilo - la esclerosis múltiple remitente-recurrente - inmunosupresores - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - fumarato de dimetilo - la esclerosis múltiple remitente-recurrente - inmunosupresores - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Unión Europea - español - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - fumarato de dimetilo - la esclerosis múltiple remitente-recurrente - inmunosupresores - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Unión Europea - español - EMA (European Medicines Agency)

sanofi belgium - alemtuzumab - esclerosis múltiple - inmunosupresores selectivos - lemtrada está indicado para pacientes adultos con esclerosis múltiple remitente recidivante (emrr) con enfermedad activa definida por características clínicas o de imagen.

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - fingolimod clorhidrato de - la esclerosis múltiple remitente-recurrente - inmunosupresores - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 y 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Unión Europea - español - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - la esclerosis múltiple remitente-recurrente - inmunosupresores - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomide - la esclerosis múltiple remitente-recurrente - los inmunosupresores selectivos de inmunosupresores - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).